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Introduction
Bendamustine (bendamustine hydrochloride) (BM) 
(4-[5-[bis-(2-chloroethyl)amino]-1-methyl-benzimidazol-
2-yl]butyric acid hydrochloride is a unique alkylating agent, 
which combines a nitrogen mustard moiety of mechlore-
thamine with a benzimidazole (Fig. 1) [1]. This cytostatic 
agent has been used in Germany since the 1970s against a 
number of malignancies [2, 3]. In 2008, BM was approved 
in the US for the treatment of chronic lymphocytic leu-
kemia (CLL) and later for indolent B cell non-Hodgkin’s 
lymphoma (NHL) [4, 5]. The mechanism of action of BM 
is unique and multifaceted. Compared to other alkylating 
agents, BM causes more extensive and long-lasting DNA 
damage which leads to a concentration-dependent apopto-
sis and non-apoptotic cell death or mitotic catastrophe [6–
8]. Thus, many clinical trials have recently focused on the 
assessment of the optimal dosage, tolerance, and efficacy 
of BM in various hematological and some solid malignan-
cies, including: CLL, NHL, Hodgkin’s disease, multiple 
myeloma, primary and metastatic brain tumors, small-cell 
lung cancer sarcomas, and other neoplasms [9–14]. Pre-
clinical and clinical studies have shown that BM demon-
strates no complete cross-resistance with the conventional 
alkylating agents, which may explain its efficacy in heavily 
pretreated, relapsed, and/or progressive malignancies [15].
BM can be used as a single agent or in combination 
with other anti-cancer agents [16, 17]. Although various 
BM dosing schemes have been attempted, the most typi-
cal protocol consists in administering BM intravenously on 
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determination of bendamustine (BM) in human plasma 
and urine were developed and validated. The procedure of 
BM extraction from a plasma sample involved solid-phase 
extraction with a C18 SPE column, while liquid–liquid 
extraction with dichloromethane was applied for a urine 
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on a Synergi Max-RP column, while FL detector was set 
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two consecutive days, every 28 days, in the dose of 100–
120 mg (m2)−1 body surface per day.
The most common side effects associated with BM 
include hematological events, such as leukopenia, neutro-
penia, thrombocytopenia, and anemia and gastrointestinal 
complications [18, 19]. It should be noted that the major 
route of BM metabolism is its hydrolysis to inactive prod-
ucts which add little or nothing to the anti-cancer effects of 
BM [16]. Thus, clinical activity against a variety of hema-
tological malignancies and solid tumors is mainly related to 
the concentration of the parent substance, which indicates 
that its dosage should be carefully adjusted for the treat-
ment of patients with a particular type of cancer [20–23]. 
Moreover, clinical trials on the use of BM in cancer chil-
dren are seldom described, which increase the risk of incor-
rect drug administration [24, 25]. Therefore, it is important 
to monitor the BM concentration in biological fluids to 
optimize efficacy and minimize any adverse effects [26].
To the best of our knowledge, only a few analytical tech-
niques have been developed for the quantification of BM in 
the presence of its metabolites in plasma [23, 27–29], urine 
[23, 27–31], bile [23, 31, 32], or mouse brain tissue [33]. 
Among them, liquid chromatography (LC) coupled with 
mass spectrometry (MS) has been the most widely used 
technique [22, 23, 27, 29–33]. Unfortunately, these meth-
odologies are scarred with a number of limitations, such as 
long analysis time and no validation data [22, 23, 27, 30–
32], 100-fold dilution of the urine sample with plasma [29], 
and low recovery of BM from brain tissue [33]. In addi-
tion, LC methods with fluorescence (FL) detection have 
been reported for the monitoring of BM in biological flu-
ids in the presence of its metabolites [22, 23, 28, 31, 32], 
respectively. However, those LC-FL techniques suffer from 
insufficient validation information [22, 23, 31, 32] and low 
efficiency of the extraction procedure [28].
The aim of this study was to develop rapid, cost-effec-
tive, and sensitive LC methods with FL detection, in com-
bination with simple sample preparation procedures suit-
able for the quantification of BM in human plasma and 
urine, which could be accessible to most pharmaceutical 
and clinical laboratories offering interesting alternatives to 
the previously published methodologies. The utility of the 
proposed LC-FL methods was demonstrated through their 
application to monitor BM in a pediatric cancer patient.
Materials and Methods
Reagents
Bendamustine hydrochloride (99.8 % purity) was supplied 
by Tocris (Bristol, United Kingdom). Cinoxacin (internal 
standard, I.S.) (99.8 % purity) came from Sigma Aldrich 
(St. Louis, MO, USA). Ortho-phosphoric acid 85 % and 
hydrochloric acid 36 % of the analytical grade were pur-
chased from POCh (Gliwice, Poland). HPLC grade ace-
tonitrile, methanol, and dichloromethane were supplied by 
Merck (Darmstadt, Germany). The organic solvents and 
reagents used for sample preparation and the mobile phase 
were used as received without further purification. The 
water used in all experiments was purified with the Milli-
Q system (Molsheim, France). LiChrolut RP-18 cartridges 
(100 mg, 1 mL) were purchased from Merck (Darmstadt, 
Germany). The control plasma and urine were obtained 
from healthy volunteers.
Chromatographic Conditions
All LC measurements were performed on an ACME 9000 
system (Younglin Instrument Corporation, Anyang, The 
Republic of Korea) equipped with a pump (SP 930D), fluo-
rescence detector RF-551 (Shimadzu, Japan), autosampler, 
thermostat (CTS30), and computer system for data acqui-
sition (AutoChro-3000). Chromatographic separation was 
carried out on a Synergi Max-RP column (150 × 4.6 mm, 
4 μm) from Phenomenex (Torrance, CA, USA) with a 
binary mixture of acetonitrile–water (25:75, v/v) adjusted 
to pH 2.7 with 85 % ortho-phosphoric acid, used as the 
mobile phase. The flow-rate was 1 mL min−1, whereas the 
column temperature was 30 °C. The analytes were moni-
tored with an FL detector set at the excitation wavelength 
of 328 nm and the emission wavelength of 420 nm, respec-
tively. A sample volume of 10 μL was injected into HPLC 
system.
Standard Solutions
The stock standard solutions of BM and the I.S. 
(1 mg mL−1) were prepared by weighing accurately 
10.0 mg of the compound of interest and diluting it in 
10 mL of methanol. Standard working solutions of BM 
were prepared daily by diluting the stock solution appro-
priately with methanol, so as to obtain the concentrations 
of 100, 10, 1 μg mL−1, and 100 ng mL−1. The inter-
nal standard stock solution was diluted further, also with 
Fig. 1  Chemical structure of bendamustine hydrochloride (BM)
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methanol, to prepare the working standard solution con-
taining 10 μg mL−1 of cinoxacin. The stock and the work-
ing standard solutions of BM were stored at −80 °C, while 
the stock standard solution of the I.S. and its working solu-
tion were stored in a refrigerator protected from light.
Plasma and Urine Standards
The calibration samples (CS) and quality control samples 
(QCs) were prepared in drug-free plasma (100 µL) and 
drug-free urine (500 µL) as fortified samples. The calibra-
tion plasma samples were prepared by spiking with the 
appropriate working standard solutions of BM to obtain ten 
concentration levels of 1, 25, 100, 250, 500, 1000, 2000, 
4000, 6000, and 8000 ng mL−1, and the I.S. concentration 
of 1500 ng mL−1. The plasma QCs were prepared with 
three BM levels (25, 500 and 6000 ng mL−1) at the I.S. 
concentration of 1500 ng mL−1, respectively.
To minimize the degradation of BM in urine, CS and 
QCs were stabilized by adding 100 μL of 6 M HCl to 
5 mL of urine prior BM spiking into the sample. In this 
final biological matrix, a set of calibration standards with 
BM levels of 5, 50, 250, 500, 1000, and 2000 ng mL−1 
at the I.S. concentration of 1500 ng mL−1 was prepared. 
QC samples were prepared by spiking the acid-treated 
human urine samples with BM to produce the concentra-
tion pools of 50, 250, and 500 ng mL−1 at the I.S. level of 
1500 ng mL−1.
Sample Preparation
Quality control plasma samples, calibration standard 
plasma samples, control blank plasma, and real clinical 
plasma samples were analyzed in the same manner. Thus, 
human plasma volumes, 100 µL each, were transferred to 
a polypropylene centrifuge tube, and the I.S. solution at the 
concentration of 1500 ng mL−1 and different concentra-
tions (1–8000 ng mL−1) of BM were added, then vortex-
mixed for 30 s. Next, 1 mL of 0.1-M hydrochloric acid was 
added to the plasma sample, which was then vortex-mixed 
for 30 s and shaken mechanically for 10 min. After centrif-
ugation for 5 min at 4 °C (8000g), solid-phase extraction 
(SPE) was performed on a LiChrolut RP-18 cartridge con-
ditioned with 1 mL of methanol and 1 mL of water before 
the sample loading. Next, the cartridge was washed with 
1 mL of 5 % methanol, and vacuum dried for 1 min. Then, 
the compounds of interest were eluted with 1 mL of metha-
nol. The whole solvent was evaporated to dryness at 50 °C 
under vacuum. Finally, the residue was reconstituted with 
50 µL of methanol, vortex-mixed for 30 s, and lastly added 
100 μL of the mobile phase. After centrifugation at 8000g 
for 5 min, the supernatant was transferred to a dark-colored 
autosampler vial, which then was stored at 2–8 °C pending 
analysis. Finally, a 10-μL aliquot sample was injected into 
the LC system.
Just as above, the quality control urine samples, cali-
bration standard urine samples, control blank urine, and 
real clinical urine samples were processed identically, and 
the final extracts were used to quantify BM. Human urine 
volumes, 500 µL each, were transferred into a polypro-
pylene centrifuge tube and vortex-mixed with 20 μL of 
6-M hydrochloric acid. Next, the I.S. solution at the con-
centration level of 1500 ng mL−1 and different concentra-
tions of BM, ranging between 5 and 2000 ng mL−1 were 
added. After vortex-mixing for 30 s, liquid–liquid extrac-
tion (LLE) was performed using 2 mL of dichlorometh-
ane. The content of the tube was vortex-mixed for 30 s, 
shaken mechanically for 10 min, and after centrifugation 
for 5 min at 4000g, the dichloromethane layer was quan-
titatively transferred into another clean glass test tube and 
evaporated to dryness at 45 °C under vacuum. The residue 
was reconstituted in 50 μL of methanol and vortex-mixed 
for 30 s, then followed by addition of 50 μL of the mobile 
phase. After centrifugation at 8000g for 5 min, the super-
natant was transferred to a dark-colored autosampler vial, 
which then was stored at 2–8 °C pending analysis. Finally, 
a 10-μL aliquot sample was injected into the LC system.
Validation of Analytical Methods
The LC methods were fully validated according to the 
requirements of the Food and Drug Administration (FDA) 
and International Conference on Harmonization of Techni-
cal Requirements for Registration of Pharmaceuticals for 
Human Use (ICH) with emphasis laid on selectivity, lin-
earity, sensitivity, accuracy and precision, and extraction 
recovery and stability [34, 35]. This assay was performed 
by assaying six replicates of the calibration standards (CS) 
and six replications of the quality control (QC) samples 
prepared in three (low, middle, and high) concentration 
levels in human plasma and urine, respectively. In both the 
cases, calibrations were performed using the least-squares 
linear regression model in the form of y = a + bx, where 
y is the peak area ratio of BM to the I.S. and x represents 
the respective standard plasma/urinary concentration of 
BM. To evaluate linearity, pooled plasma was spiked with 
the working standard solutions of BM to obtain concentra-
tions in the range of 1–8000 ng mL−1 at the I.S. level of 
1500 ng mL−1, respectively. As for the urine samples, these 
were spiked with BM in the range of 5–2000 ng mL−1 at 
the I.S. concentration of 1500 ng mL−1, respectively. Both 
plasma and urine calibration samples were analyzed on the 
same day.
The limit of detection (LOD) was measured as the sam-
ple concentration for which the area peak was three times 
that of the baseline noise. The lower limit of quantification 
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(LLOQ) was defined as the lowest concentration for which 
the ratio of the signal-to-noise was higher than 10, and 
which could be analyzed with the accuracy of ±20 % and 
precision ≤15 %.
Selectivity of the method was determined by an LC anal-
ysis of six blank plasma and six urine samples of different 
origins for peak interference in the BM and I.S. retention 
times.
To assess the intra- and inter-day precision and accu-
racy, parallel analytical runs were performed on the same 
day, and on 6 days over 2 months, respectively. Therefore, 
intra-day precision and accuracy were measured by the six-
fold replicate analysis of CS at each concentration used to 
prepare the calibration plots in plasma and urine, respec-
tively. Inter-day precision and accuracy were determined 
by an analysis of QC samples: 25, 500, and 6000 ng mL−1 
for BM in plasma, and 50, 250, and 500 ng mL−1 for BM 
in urine, respectively. The I.S. concentration in the plasma 
and urine QC samples was identified as 1500 ng mL−1. 
Precision was expressed as the relative standard deviation 
(RSD), whereas accuracy was established as the percent-
age difference between the measured concentration and the 
nominal concentration.
The absolute extraction recoveries of BM from plasma 
and urine were determined by comparing the peak areas of 
the compounds of interest in the extracted plasma and urine 
samples with the non-extracted ones at equivalent concen-
trations (100 and 1000 ng mL−1 for BM, respectively). 
Each sample was analyzed in triplicate. The absolute recov-
ery of the I.S. in the plasma and urine samples was deter-
mined for the concentration of 1500 ng mL−1 (n = 6).
Several stability tests were performed as part of valida-
tion under various conditions, including short-term stability 
(at room temperature for 4 h), long-term stability (frozen at 
−80 °C for 3 months), freeze/thaw stability (three cycles 
from −80 °C to room temperature), and post-preparative 
storage (at 4 °C for 24 h), for fortified plasma and urine 
samples at low, medium, and high QC concentrations of 
BM. In each test stability assay, three replicates were ana-
lyzed using the proposed LC methods.
Method Application
The LC method was used to determine the levels of BM 
in human plasma and urine after intravenous infusion of 
the compound to a child with refractory and progressive 
Hodgkin’s lymphoma for two consecutive days. The boy’s 
age was 17, and his weight was 50 kg. The condition of the 
patient was established through medical history, and clini-
cal and laboratory examinations. Both the parents and the 
patient read the protocol and gave their written informed 
consent before joining the study. The clinical protocol 
was approved by the Ethical Committee of the Medical 
University of Gdan´sk (Gdan´sk, Poland). BM was adminis-
tered in monotherapy as a 60-min intravenous (IV) infusion 
at the dose of 120 mg (m2)−1 body surface per day, for two 
consecutive days.
Venous blood samples (4 mL each) were collected in 
K2EDTA tubes at 0 (pre-dose baseline), 0.5, and 1.0 h after 
the initiation of the first infusion, and at 1, 2, 3, 4, 6, 8, 12, 
18, and 23 h after the end of the first infusion. Then, blood 
sample collection continued over the second infusion (0.5 
and 1 h), and after 1, 2, 3, 4, 6, 8, 12, 18, 24, 48, and 72 h 
following the completion of the second BM infusion. All 
plasma samples were immediately separated by centrifu-
gation at 3000g for 10 min, and the obtained plasma was 
stored at −80 °C up to the LC analysis.
Urine samples were collected after the first IV infusion 
of BM (12.00 a.m.), at 14.00; 17.25; 9.50, as well as before 
the second IV infusion (11.50) (1st day); and after the sec-
ond IV infusion (12.00 a.m.) at 14.00; 17.00; 21.40; 9.40 
(2nd day), as well as at 12.00 (3rd day), and at 12.00 (4th 
day) after the end of drug infusion. Moreover, 24-h urine 
samples after day 1 and day 2 of BM administration were 
collected. To prevent chemical hydrolysis of BM, each 
urine sample (5 mL) was immediately frozen and stored 
at −80 °C in a polypropylene tube previously treated with 
100 μL of 6 M HCl.
Results and Discussion
In view of pharmacokinetic and biomedical studies, the 
aim of this study was to develop the sensitive LC methods 
with fluorescence detection for the quantification of BM 
in human plasma and urine to offer an interesting alterna-
tive to the LC methodologies previously reported in the 
literature [22, 23, 27–33]. Thus, a lot of experiments were 
conducted to identify the optimal conditions of sample col-
lection and storage, to develop a simple sample preparation 
procedure, and to establish the chromatographic parameters 
for the LC analysis of BM in biological fluids.
Method Development
Sample Collection and Storage
The literature data on stability of nitrogen mustard-contain-
ing compounds, such as BM, indicate that the substances 
are unstable in aqueous solutions because of degradation 
by hydrolysis [36–38]. Moreover, the process is strictly pH 
dependent. For example, the BM loss was higher at pH 7.6 
than the loss levels observed at pH 6.5, with the lowest BM 
degradation found at a pH < 3 [29, 37]. Therefore, follow-
ing the literature data, various options for storing BM urine 
samples were investigated, including the addition of 6-M 
HCl-NaCl (1–10 mL urine) [22, 23, 28, 32], and 100-fold 
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dilution in human plasma which enabled processing and 
analyzing the urine-plasma samples in the same manner 
as the human plasma samples [29]. On the other hand, this 
step might also decrease the reliability of BM quantifica-
tions in urine because of a significant dilution of the real 
clinical sample.
In the presented study, 100 μL of 6-M HCl was added 
to each tube prior urine sample loading (5 mL) to prevent 
chemical hydrolysis of BM. The samples were immedi-
ately frozen and stored at −80 °C up to the LC analysis. 
This procedure can be deemed an interesting alternative to 
using 6-M HCl-NaCl, because the lesser degradation of the 
biological matrix, combined with decreased dilution of the 
urine sample (1:10 vs 1:50, v/v), enables improving sensi-
tivity and reliability of the BM assay in urine samples.
Optimization of Sample Preparation
When developing the sample preparation procedure, 
various organic solvents, such as tert-butyl methyl ether 
(TBME), ethyl acetate, and dichloromethane were used for 
liquid–liquid extraction (LLE) of BM from human plasma 
samples. Moreover, solid-phase extraction (SPE) proce-
dures using C18, C8, and hydrophilic-lipophilic balance 
(HLB) cartridges, and three solvents for the elution of the 
compounds of interest (acetonitrile, methanol, and dichlo-
romethane) were tested. The efficiency of each studied pro-
cedure was determined on the basis of the LC analysis of 
plasma samples spiked with BM at the levels of 100 and 
1000 ng mL−1, then compared to the absolute recovery data 
calculated for other procedures studied. Moreover, signal-
to-noise ratios were calculated, expressed as: the area peak 
of the analyte in the spiked biological sample, and the sig-
nal area for the same retention time in the blank biological 
sample. The assay was performed to evaluate the clean-up 
of the matrix background. The obtained mean recovery 
data (mean ± SD) for BM from plasma samples are shown 
in Table S1 (see Electronic Supplementary Material). The 
results visualize that the highest efficiency of the tested 
LLE in plasma samples was found when dichlorometh-
ane was used as the extraction solvent (76.6 ± 5.4 %), but 
the BM recovery ratio was lower than for the SPE proce-
dures. Among the latter, the SPE methods based on a LiCh-
rolut RP-18 cartridge were the most efficient. It was also 
observed that the best elimination of the ballast substances 
from the plasma matrix was achieved for dichlorometh-
ane (data not shown); however, the disadvantage was 
lower recovery of BM (94.0 ± 5.4 %) than after the use 
of methanol (99.8 ± 3.5 %). Thus, methanol was finally 
selected for further studies because of higher clean-up of 
the plasma background and the highest recovery of BM. In 
those SPE conditions, the rate of recovery for the I.S. was 
97.5 ± 3.8 %.
When optimizing the sample preparation procedure for 
urine samples, 20 μL of 6-M HCl was added to thawed 
urine (0.5 mL) to achieve a low pH biological matrix, and 
thus minimize BM degradation. Next, all of the above-
described sample preparation procedures were also used. 
Unfortunately, the application of all studied SPE proce-
dures brought unsatisfactory results irrespective of the 
urine volume loaded to the SPE cartridges (100–500 μL). 
That was due to insufficient clean-up of the urine back-
ground from the ballast substances in the retention times of 
both the BM and the I.S. (data not shown). Out of the tested 
LLE procedures, the highest obtainable clean urine extract 
combined with high recovery of BM was found when 
dichloromethane was used (Electronic Supplementary 
Material see Table S1). In the proposed LLE method, the 
rate of recovery for the I.S. (cinoxacin) was 98.5 ± 6.5 %.
These data evidence that the efficiency of BM extraction 
from plasma based on the developed SPE with C18 car-
tridges was higher than that of using protein precipitation 
with 10 % perchloric acid/methanol solution (68.7–72.2 % 
for BM) [28], or SPE with HLB Oasis columns (76.4–
82.8 % for BM) [29], or protein precipitation with metha-
nol for brain tissues (41.1–69.2 % for BM) [33]. Notewor-
thy, the rate of recovery of BM from urine based on LLE 
with dichloromethane was also higher than the rates of the 
methods earlier reported in the literature [29, 33]. Thus, 
both SPE with C18 and LLE using dichloromethane can be 
considered as interesting alternatives to the previous pub-
lished sample preparation procedures.
Optimization of LC Parameters
For the optimization of the LC conditions for BM determi-
nation, several analytical columns like Synergi Polar-RP, 
Discovery HS C18, Synergi Hydro-RP, InertSustain C18, 
and Synergi Max-RP were tested and compared for their 
signal response to BM, the peak shape, and the retention 
times. Finally, the Synergi Max-RP (4.6 mm × 150 mm, 
4 µm) column was chosen to quantify BM in human plasma 
and urine, because of its highest signal response to BM, its 
symmetric peak shape, and the acceptable retention time. 
This column, but having different dimensions, was also 
used for the quantification of BM in the presence of its 
metabolites described by Teichert et al. [22, 23, 32].
When the mobile phase composition was optimized, 
various mixtures of acetonitrile and/or methanol with water 
were prepared at different proportions, following which 
the pH of those mobiles phases was adjusted with 85 % 
ortho-phosphoric acid to 2.5, 2.7, 2.9, 3.1, 3.3, and 3.5. The 
mixture of acetonitrile and water in the ratio of 25:75 (v/v, 
pH 2.7) was chosen as optimal for the LC separation of 
BM, since it ensures good peak separation and appropriate 
retention times. It should also be noted that the acidic pH of 
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the mobile phase in the LC separation was able to prevent 
chemical hydrolysis of BM, whereas the isocratic elution of 
the mobile phase can considered as an interesting alterna-
tive to earlier described gradient mode LC methods for BM 
quantification in biological samples [22, 23, 27, 29–33].
Other experimental parameters, such as the column tem-
perature and the flow-rate of the mobile phase, were also 
tested. Thus, increasing the column temperature and the 
flow-rate of the mobile phase caused shortened the reten-
tion times of the BM and the I.S., but the signal peaks of 
the analytes interfered with the peaks of the endogenous 
matrix substances. In effect, the LC separation at 30 °C 
and the flow-rate of 1 mL min−1 were chosen as a good 
compromise between shorter retention times and the best 
resolution.
With the view of optimizing the fluorescence detection 
conditions, different excitation wavelengths (315–340 nm) 
and emission wavelengths (410–435 nm) were tested. The 
highest response signals for BM were observed at the exci-
tation wavelength of 328 nm and emission wavelength of 
420 nm, respectively. Hence, these parameters of FL detec-
tion were finally selected for further study. Those results 
corroborated the data previously reported in the literature 
[22, 23, 28, 32].
The developed isocratic mode LC conditions for the 
quantification of BM in biological fluids offer satisfac-
tory separation of BM at a shorter analysis run time 
(10 min) compared to the previously reported LC-FL tech-
niques—70 min [22, 23, 32] and 14 min [28], respectively. 
This analysis time is comparable to the time obtained for 
the gradient mode LC–MS/MS, 11 min [29] and 8.2 min 
[33], but significant shorter than required for the LC–MS/
MS method with off-line radioactivity detection (180 min) 
[30], respectively. In effect, the proposed LC-FL methods 
can be considered as interesting alternatives for most phar-
maceutical and clinical laboratories.
Validation of Analytical Methods
For method validation purposes, the calibration samples 
(CS) and quality control samples (QCs) were prepared as 
described in “Plasma and Urine Standards”, and treated 
in the same manner as reported in “Sample Preparation”, 
then analyzed in the LC conditions described in “Chro-
matographic Conditions”. One of the important aspects of 
the validation of the method was the choice of the internal 
standard. For this propose, cinoxacin was selected, because 
this drug offers good solubility in the most organic sol-
vents and possess natural fluorescence activity in the range 
required for BM. In addition, the retention time of cinoxa-
cin was optimal in chromatographic conditions used for 
BM assay. Moreover, this substance is not used in human 
medicine.
Selectivity
Selectivity was evaluated by comparing chromatograms of 
drug-free blank human plasma and those of urine samples 
and the ones of extracts from plasma and urine containing 
BM and the I.S., respectively, all tested for interference 
using the proposed LC methods (n = 6). Representative 
chromatograms of drug-free plasma and plasma spiked 
with 500 ng mL−1 of BM and with the I.S. at the level of 
1500 ng mL−1 are shown in Fig. 2a and b, respectively. 
Typical chromatograms of drug-free urine and urine spiked 
with 500 ng mL−1 of BM and with the I.S. at the concen-
tration of 1500 ng mL−1 are presented in Fig. 3a and b, 
respectively. The chromatograms confirm that no interfer-
ences were detected from the substances of the endogenous 
matrix in the area, where BM and the I.S. appear.
Linearity
The linearity of the method was confirmed over the concen-
tration ranges of 1–8000 and 5–2000 ng mL−1 for BM in 
plasma and urine, respectively. The corresponding calibra-
tion parameters of both calibration curves are summarized 
in Table 1. The data confirm that the calibration curves 
demonstrated good linearity for both plasma and urine, 
with the correlation coefficients (R2) higher than 0.9996, 
which indicate excellent linearity of the methods within the 
considered linear ranges.
Limits of Detection and Quantification
The limits of detection (LOD) were measured for six inde-
pendently made replications and were found to be 0.5 and 
2.5 ng mL−1 for BM in plasma and urine, respectively. 
The lower limits of quantification (LLOQ) for BM were 
estimated by the six-fold replicate analysis, and found to 
stay at the level of 1 and 5 ng mL−1 in plasma and urine 
samples, respectively. The LLOQ for BM were also the 
lowest standard concentrations in both calibration curves 
(Table 1). The LLOQ parameters were lower than those 
published heretofore for the LC-FL assay of BM in plasma 
[28], LC–MS/MS determination in urine [27, 29], and 
mouse brain tissue [33], while being comparable to those 
obtained by LC-FL for BM in urine [28], even though 
lower plasma and urine volumes were used (100 vs 200–
250 μL for plasma and 500 vs 1000 μL for urine, respec-
tively) [22, 23, 28, 29, 32].
Precision and Accuracy
The intra-day and inter-day precision and accuracy results 
for both the LC methods are summarized in Table 2. The 
data confirmed that intra-day precisions for BM in plasma 
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and urine were below 9.65 and 9.86 %, while intra-day 
accuracies were higher than 92.63 and 94.29 %, respec-
tively. The inter-day precisions did not exceed 9.82 and 
9.02 %. The inter-day accuracies ranged from 100.26 to 
101.16 % and between 99.75 and 101.74 %, respectively. 
Those data confirmed that the intra-day and inter-day accu-
racy and precision values met the generally accepted crite-
ria for bioanalytical method validation at all calibration and 
QC concentration levels [34, 35].
Recovery
The extraction recoveries of BM from plasma and urine 
were measured at two different concentration levels (low 
and high), six replicates for each concentration. The 
obtained recovery data for BM are summarized in Table 
S1 (see Electronic Supplementary Material). The I.S. 
(cinoxacin) recovery rate from human plasma using SPE-
C18 was attained at 97.5 ± 3.8 %, whereas the value of 
98.5 ± 6.5 % was calculated for the urine sample after the 
LLE with dichloromethane. These extraction recovery data 
confirm that the developed sample preparation procedures 
can assure adequate sensitivity for processing plasma and 
urine samples for the LC assay of BM. Moreover, these 
procedures are more effective than the previously reported 
methods [28, 29, 33].
Stability Tests
Stability tests for various conditions, as described in the 
section “Validation of Analytical Methods”, were con-
ducted by assessing plasma and urine samples at three QC 
levels of BM. Representative chromatograms of plasma 
spiked with 500 ng mL−1 of BM and with the I.S. at the 
level of 1500 ng mL−1 obtained in short-term stability and 
long-term stability tests are shown in Fig. S1a and S1b, 
whereas the chromatograms performed in freeze/thaw sta-
bility and post-preparative storage tests are presented in 
Figure S2c and S2d, respectively (see Electronic Supple-
mentary Material). Typical chromatograms of urine spiked 
Fig. 2  Typical chromato-
grams of the blank human 
plasma extract (a) and of a 
plasma sample spiked with 
BM (1) (500 ng mL−1) and 
cinoxacin (I.S.) at the level of 
1500 ng mL−1 (b) after the SPE 
using the C18 cartridges
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with 250 ng mL−1 of BM and with the I.S. at the level of 
1500 ng mL−1 obtained in four stability tests are illus-
trated in Figs. S3 and S4, respectively (see Electronic Sup-
plementary Material). All stability evaluations were based 
on back-calculated concentrations. The resulting data are 
summarized in Table 3 revealed no significant degradation 
of BM in the plasma and urine samples. Thus, all samples 
prove stable and could be handled in normal laboratory 
conditions without any significant loss, if under the condi-
tions described above.
Method Application to the Real Plasma and Urine Samples
It should be noticed that clinical trials on the application of 
BM in cancer children are seldom reported which causes 
higher risk of incorrect drug administration [24, 25]. In 
effect, the efficacy of the therapy and high level of adverse 
effects can be observed [26].
The developed LC methods have been successfully used 
in monitoring of BM administered to a 17-year-old boy with 
refractory progressive Hodgkin’s lymphoma, in the form of 
60-min IV infusions at a dose of 120 mg (m2)−1 body sur-
face each, on two consecutive days. The representative LC 
Fig. 3  Typical chromatograms 
of the blank human urine extract 
(a) and of a urine sample spiked 
with BM (1) (500 ng mL−1) and 
cinoxacin (I.S.) at the level of 
1500 ng mL−1 (b) after the LLE 
with dichloromethane
Table 1  Summary of validation data for BM determination in human 
plasma and urine by the LC-FL methods (n = 6)
Plasma Urine
Linearity (ng mL−1) 1–8000 5–2000
Equation parameter
 Slope 0.0040 ± 0.00002 0.0021 ± 0.00002
 Intercept 0.0127 ± 0.0620 −0.0043 ± 0.0201
 Standard error 0.152 0.0363
 Correlation coefficient  
(R2)
0.9998 0.9996
 LOD (ng mL−1) 0.5 2.5
 LLOQ (ng mL−1) 1.0 5.0
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chromatograms of the plasma and urine extracts obtained 
from the patient after the first IV BM infusion are shown in 
Fig. 4a–c, respectively. The calculated profile of the plasma 
concentration–time for BM is presented in Fig. 5a, while 
the urinary concentrations of BM collected during and after 
the IV drug infusion are shown in Fig. 5b, respectively. 
Thus, according to the plasma profile of BM, Cmax at the 
level of 7015.3 ± 34.5 and 7245.4 ± 42.8 ng mL−1 for BM 
was observed at time of the first and the second IV infu-
sion (Tmax = 1 h) (Fig. 5a). This BM profile obtained in our 
patient is comparable to the profiles previously reported for 
pediatric patients after an IV infusion of BM at the dose 
Table 2  Intra-day and inter-day precision and accuracy for the determination of BM in plasma and urine samples by SPE-LC and LLE-LC tech-
niques, respectively
Than 9.86 % while the accuracies were in the range of 92.63–107.92 and 94.29–103.54 %
Intra-day (n = 6) Inter-day (n = 6)








Spiked Found (mean ± SD) Spiked Found (mean ± SD)
Plasma
 1 1.08 ± 0.10 9.65 107.92 25 25.29 ± 2.48 9.82 101.16
 25 24.08 ± 2.06 8.54 96.30 500 501.28 ± 5.64 1.12 100.26
 100 106.58 ± 7.75 7.27 106.58 6000 6018.21 ± 48.73 0.81 100.30
 250 231.58 ± 13.42 5.79 92.63
 500 489.08 ± 23.93 4.89 97.82
 1000 1034.08 ± 38.50 3.72 103.41
 2000 2049.08 ± 41.50 2.03 102.45
 4000 3926.58 ± 62.91 1.60 98.16
 6000 6049.08 ± 66.24 1.10 100.82
 8000 8029.08 ± 43.99 0.55 100.36
Urine
 5 4.71 ± 0.46 9.86 94.29 50 49.87 ± 4.50 9.02 99.75
 50 49.19 ± 4.23 8.59 98.38 250 254.34 ± 10.47 4.12 101.74
 250 249.67 ± 15.94 6.38 99.87 500 505.49 ± 3.73 0.74 101.10
 500 487.76 ± 19.98 4.10 97.55
 1000 1035.38 ± 24.28 2.35 103.54
 2000 2002.05 ± 31.15 1.56 100.10
Table 3  Stability of BM in 
plasma and urine samples 
(n = 3)
Plasma Concentration (ng mL−1)
25 500 6000
Accuracy (mean ± SD) (%)
Short-time stability 97.7 ± 7.8 101.7 ± 5.5 102.1 ± 6.8
Long-time stability 109.9 ± 6.9 95.9 ± 3.9 98.1 ± 8.9
Freeze/thaw stability 95.7 ± 6.7 102.6 ± 8.1 96.6 ± 7.8
Post-preparative storage 103.9 ± 3.9 98.3 ± 6.9 101.2 ± 7.9
Urine Concentration (ng mL−1)
50 250 500
Accuracy (mean ± SD) (%)
Short-time stability 103.4 ± 4.9 102.9 ± 7.9 96.6 ± 6.6
Long-time stability 104.3 ± 8.8 94.7 ± 5.5 97.9 ± 4.1
Freeze/thaw stability 93.9 ± 3.9 96.9 ± 3.9 95.9 ± 3.9
Post-preparative storage 99.7 ± 4.4 101.3 ± 6.6 101.7 ± 7.3
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of 120 mg (m2)−1 [24, 25]. Urinary concentrations of BM 
were significantly lower than those observed in plasma 
(Fig. 5b), what confirms that this drug undergoes extensive 
metabolism. Specifically, the BM concentrations of 11.3 
and 7.3 ng mL−1 were found in 24-h urine samples after 
the first and the second IV BM infusion, respectively. The 
results stay in line with the previously reported literature 
data [23–25, 27–29].
Fig. 4  Representative LC 
chromatograms of human 
extracts obtained from a 
17-year-old patient with refrac-
tory progressive Hodgkin’s 
lymphoma, after IV infusions 
at the dose of 120 mg (m2)−1 
body surface per day, adminis-
tered for two consecutive days 
at the following BM levels 
(1): a 7015.36 ng mL−1 in the 
plasma sample collected after 
the end of the first IV infusion; 
b 487.37 ng mL−1 in the plasma 
sample collected 1 h after the 
end of the first IV infusion; and 
c 13.18 ng mL−1 in the urine 
sample collected at 21.40 after 
the second IV infusion (12.00 
a.m.), and cinoxacin (I.S.) at the 
concentration of 1500 ng mL−1
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Conclusions
In brief, fast, precise, and accurate LC-FL methods for 
quantification of BM in human plasma and urine, where 
cinoxacin was used as the internal standard, were devel-
oped and validated. As concerns plasma samples, the 
sample preparation procedure involved the application of 
the SPE with C18 cartridges, while a one-step LLE with 
dichloromethane was applied for the extraction of BM 
from urine. In both the cases, the LC analysis of BM was 
carried out on the Synergi Max-RP in the isocratic mode. 
The proposed methods are time-saving and economical; 
furthermore, they are suitable for analyzing large numbers 
of plasma and urine samples for drug monitoring, pharma-
cokinetic, and biomedical investigations. Finally, the pre-
sent LC-FL techniques have been successfully used for the 
monitoring of BM after an IV infusion of BM to a child 
with refractory progressive Hodgkin’s lymphoma.
Fig. 5  BM concentration profiles in the plasma (a) and urine (b) of a 17-year-old patient with NHL, after IV infusions at the dose of 120 mg 
(m2)−1 body surface per day, administered for two consecutive days
872 A. Plenis et al.
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